Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

real-time surveillance

- PMLiVE

Pfizer CEO says oral COVID-19 pill could be ready by the end of the year

Company initiated a phase 1 study of the drug last month

- PMLiVE

EU moves forward with legal action against AZ over vaccine supply issues

Legal proceeding launched on the basis of 'breaches of the advanced purchase agreement'

- PMLiVE

WHO to review Moderna’s COVID-19 vaccine for emergency use listing this week

WHO is also due to review vaccines from Sinopharm and Sinovac for possible EUAs

dengue fever mosquito

Oxford University’s malaria vaccine is 77% effective

First vaccine to meet WHO-specified efficacy goal of 75%, says research team

- PMLiVE

J&J resumes US rollout of single-dose COVID-19 vaccine

CDC and FDA recommended pause be lifted after ‘rigorous review’ of very rare blood clots

- PMLiVE

Single dose of COVID-19 vaccines ‘significantly’ reduces infections

Infections fell by 65% after first dose of AZ/Oxford or Pfizer/BioNTech vaccines

- PMLiVE

EU may seek legal action against AstraZeneca following vaccine supply cuts

EU supply issues for the AZ vaccine started in January 2021

- PMLiVE

J&J halts manufacturing of COVID-19 at US plant after FDA warning

Inspection report found facility was “not maintained in a clean and sanitary condition”

Leaders in Pharma: Samir Vattompadam

In the inaugural episode of Impetus Digital's Leaders in Pharma podcast, I sit down with Samir Vattompadam. Samir is currently Vice President, Program Executive for EQRx.

Impetus Digital

Building Better Access to Pediatric Care Through Telehealth

Jeannie Chen, Head of Clinical Operations and People at Hazel Health, shares her insights on telemedicine and virtual care as means to improve healthcare access and equity among school-aged children....

Impetus Digital

- PMLiVE

Adding insult to injury

Hey Europe, it may be time to consider that ‘less is more’

- PMLiVE

Valneva to compare its COVID-19 vaccine candidate to AstraZeneca’s jab

Phase 3 trial will test Valneva’s vaccine candidate against Vaxzevria in approximately 4,000 participants

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links